市場調査レポート

商品コード

1458102

幹細胞治療の世界市場規模、シェア、成長分析、治療法別、用途別-産業予測、2024～2031年

Global Stem Cell Therapy Market Size, Share, Growth Analysis, By Therapy(Autologous, and Allogenic), By Application(Regenerative Medicine, Drug Discovery and Development) - Industry Forecast 2024-2031

出版日: 2024年03月25日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 836,870円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 978,980円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,121,090円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.90円

全表示
概要
目次

概要

サンプル依頼リストに入れる

幹細胞治療の世界市場規模は、2022年に121億1,000万米ドルと評価され、予測期間（2024～2031年）のCAGRは10.1%で、2023年の133億3,000万米ドルから2031年には287億9,000万米ドルに成長する展望です。

幹細胞治療業界の主要目標は、様々な疾患に対する最先端のソリューションを提供することです。幹細胞治療の目標は、現在有効な治療法がほとんどない、あるいは代替療法がない病気や怪我を治療することです。この市場は、幹細胞の再生能力を活用することで、心血管疾患、神経障害、整形外科的損傷、自己免疫疾患、ある種のがんなどの病気を抱える患者に希望を与えることを目的としています。加齢に伴う病気や慢性疾患の増加もその主要原因の一つです。

幹細胞治療の高価格は主要障害の一つです。幹細胞治療市場には数多くの障害が立ちはだかっています。規制や標準化の必要性は主要障害の一つです。幹細胞治療の開発、製造、臨床応用に関する正確な規範や基準を確立することは、これらの治療が進歩するにつれてますます重要になってきています。費用対効果と拡大性は、市場が直面している2つの問題です。克服すべき大きな障害のひとつは、幹細胞治療の品質とコストを抑えつつ、需要を満たすために生産量を増やすことです。こうした困難にもかかわらず、幹細胞治療市場は多くの可能性を秘めています。幹細胞治療の可能性を検討する臨床試験や調査研究の数が増加していることは、明るい未来を示唆しています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

幹細胞治療の世界市場：治療法別

市場概要
自家移植
同種異系

幹細胞治療の世界市場：用途別

市場概要
再生医療
創薬と開発

幹細胞治療の世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

Novartis AG（スイス）
Pfizer Inc.（米国）
Mesoblast Limited（オーストラリア）
Celgene Corporation（a subsidiary of Bristol Myers Squibb）（米国）
TiGenix NV（a subsidiary of Takeda Pharmaceutical Company Limited）（ベルギー）
Gamida Cell Ltd.（イスラエル）
Vericel Corporation（米国）
Medipost Co., Ltd.（韓国）
Astellas Pharma Inc.（日本）
Osiris Therapeutics, Inc.（米国）
NuVasive, Inc.（米国）
Cynata Therapeutics Limited（オーストラリア）
Cellular Dynamics International（FUJIFILM Holdings Corporationの子会社）（米国）
Lonza Group Ltd.（スイス）
Caladrius Biosciences, Inc.（米国）
Athersys, Inc.（米国）
Cytori Therapeutics, Inc.（米国）
Holostem Terapie Avanzate S.r.l.（イタリア）
Pluristem Therapeutics Inc.（イスラエル）
BioTime, Inc.（米国）

Product Code: SQMIG35H2162

Global Stem cell therapy Market size was valued at USD 12.11 Billion in 2022 and is poised to grow from USD 13.33 Billion in 2023 to USD 28.79 Billion by 2031, at a CAGR of 10.1% during the forecast period (2024-2031).

The main goal of the stem cell therapy industry is to offer cutting-edge solutions for a variety of illnesses. The goal of stem cell therapies is to treat illnesses and injuries for which there are currently few or no effective therapy alternatives. This market aims to give patients with ailments like cardiovascular diseases, neurological disorders, orthopedic injuries, autoimmune diseases, and some kinds of cancer hope by utilizing the regenerative characteristics of stem cells. the expansion of the market for stem cell therapy worldwide. The rising incidence of age-related illnesses and chronic disorders is one of the main causes.

The high price of stem cell treatments is one of the main obstacles. Numerous obstacles confront the market for stem cell therapy. The requirement for regulation and standardization is one of the main obstacles. Establishing precise norms and standards for stem cell therapy development, manufacturing, and clinical application is becoming more and more important as these treatments progress. Cost-effectiveness and scalability are two issues the market is facing. One major obstacle that still needs to be overcome is increasing the production of stem cell therapies to satisfy demand while keeping quality and costs down. Despite the difficulties, the market for stem cell therapy presents a lot of potential. A bright future is suggested by the growing number of clinical trials and research investigations examining the potential of stem cell therapy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Stem Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Stem Cell Therapy Market Segmental Analysis

The therapy, application, and geographic segments of the worldwide stem cell therapy market are divided up. The market is divided into two categories for therapy: autologous and allogeneic. The market is divided into three categories based on application: drug development, regenerative medicine, and discovery. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.

Drivers of the Global Stem Cell Therapy Market

One major factor propelling the stem cell therapy market is the increasing prevalence of chronic diseases like neurological illnesses, orthopedic injuries, and cardiovascular ailments. With the ability to repair damaged tissues and organs, stem cell therapies offer patients new therapy options when there are few or no other viable options.

Restraints in the Global Stem Cell Therapy Market

One major obstacle to the broad acceptance of stem cell therapies is their high cost. The cost of these treatments is considerable due in part to the complexity of manufacturing, research and development activities, and regulatory restrictions. This restricts many patients' access to stem cell treatments, especially in areas with lower incomes.

Market Trends of the Global Stem Cell Therapy Market

A greater emphasis is being placed on allogeneic therapies: these treatments, which employ donor cells, have become more popular. Benefits of this technique include lower production costs, uniform and easily accessible cell sources, and maybe off-the-shelf therapies. There is a growing pipeline of clinical trials and product development in the field of allogeneic cell therapy as a result of numerous companies refocusing their efforts on this area.

Personalized Medicine and Cell Banking: The field of personalized medicine, which involves customizing treatment plans for each patient according to their specific traits, is becoming more and more popular in the stem cell therapy industry. The process of collecting and preserving human cells for potential therapeutic applications, known as cell banking, is gaining significance. This strategy makes it possible to provide prompt, individualized treatment alternatives, especially in autologous therapies, which use the patient's own cells.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Stem Cell Therapy Market by Therapy

Market Overview
Autologous
and Allogenic

Global Stem Cell Therapy Market by Application

Market Overview
Regenerative Medicine
Drug Discovery and Development

Global Stem Cell Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gamida Cell Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medipost Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Osiris Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NuVasive, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cynata Therapeutics Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caladrius Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Holostem Terapie Avanzate S.r.l. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluristem Therapeutics Inc. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioTime, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments